Cryo-Cell International Inc CCEL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2026 Financial Results
-
Cryo-Cell Receives Acceptance of Compliance Plan From NYSE American
-
Cryo-Cell International Receives FACT Re-accreditation, Setting the Longest Independently Validated Quality Track Record Among U.S. Private Cord Blood Banks
Trading Information
- Previous Close Price
- $3.48
- Day Range
- $3.46–3.80
- 52-Week Range
- $0.00–5.43
- Bid/Ask
- $3.25 / $3.67
- Shares Outstanding
- 8.06M
- Market Cap
- $28.62M
- Volume/Avg
- 16,781 / 8,917
Key Statistics
- Price/Earnings (Normalized)
- 1,561.24
- Price/Sales
- 0.90
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 0.29%
Company Profile
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Stock Style Box
- Small Core
- Total Number of Employees
- 76
- Website
- https://www.cryo-cell.com
Valuation
|
Metric
|
CCEL
|
|---|---|
Price/Earnings (Normalized) | 1,561.24 |
Price/Book Value | — |
Price/Sales | 0.90 |
Price/Cash Flow | 11.84 |
Price/Earnings
CCEL
Financial Strength
|
Metric
|
CCEL
|
|---|---|
Quick Ratio | 0.63 |
Current Ratio | 0.71 |
Interest Coverage | −0.32 |
Quick Ratio
CCEL
Profitability
|
Metric
|
CCEL
|
|---|---|
Return on Assets (Normalized) | 4.17% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
CCEL
Medical Care Facilities Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| HCA Healthcare Inc
HCA
| LOCK|Ygp#X!$ | LOCK|PS@^ | $84B | |||
| Fresenius SE & Co KGaA ADR
FSNUY
| — | LOCK|JpypN | $27B | |||
| IHH Healthcare Bhd
IHHHF
| — | LOCK|FSW#L | $19B | |||
| Tenet Healthcare Corp
THC
| LOCK|!p@KC% | LOCK|<k$xC | $17B | |||
| DaVita Inc
DVA
| LOCK|@?x&#>! | LOCK|!^>!< | $15B | |||
| Fresenius Medical Care AG
FMCQF
| — | LOCK|$$x& | $13B | |||
| Fresenius Medical Care AG ADR
FMS
| LOCK|f$PSFL? | LOCK|$YyGS | $13B | |||
| Encompass Health Corp
EHC
| — | LOCK|!Jh! | $11B | |||
| Universal Health Services Inc Class B
UHS
| LOCK|%<##@% | LOCK|MtR?d | $9B | |||
| Genesis Healthcare Inc Class A
GENNQ
| LOCK|mr@ | LOCK|Yx | $12,220 |
United States